Home>Topics>>Oramed Readies Oral Insulin Study In U.S.

Oramed Readies Oral Insulin Study In U.S.

Israel Stocks News and Analysis from Seeking Alpha

Tue, 7 May 2013

By Len Zehr : Oramed Pharmaceuticals (NASDAQ: ORMP ) is awaiting a decision from the FDA, possibly later this week, to conduct a sub-study of the safety of its oral insulin candidate, ORMD-0801, before proceeding to a large, multi-center Phase 2 clinical trial later this year. "Approving a clinical ...
Content Partners